Journal Digest: Discrimination and Alcohol Abuse; COVID-19 Education and Stress; Bumetanide and ASD Symptoms; OUD Patients and Hospitalization
Discrimination May Increase Risk of Severe Alcohol Use in Minorities
iStock/VadimZakirov
Racial and ethnic discrimination may increase the risk that members of minority groups will experience severe alcohol use disorder (AUD), according to a report in Drug and Alcohol Dependence.
“Our findings [should] prompt researchers and practitioners to consider the extent to which systems of oppression can impact the pathogenesis, trajectories, and recoveries (including relapse) of AUD,” wrote researchers from Kaiser Permanente Washington Health Research Institute and colleagues.
The authors analyzed data from 17,115 racial/ethnic minorities who participated in the National Epidemiological Survey on Alcohol-Related Conditions III (NESARC-III), a national survey that took place in 2012-2013. This included the responses of individuals who identified as American Indian or Alaskan Native; Asian, Native Hawaiian, or Other Pacific Islander; Black or African American; and Hispanic or Latino.
During in-person interviews, participants were evaluated using the AUD and Associated Disabilities Interview Schedule-5. (AUD severity levels were classified as mild, moderate, or severe: endorsing 2−3, 4–5, or ≥6 DSM-5 criteria, respectively.) The participants were also asked how often in the past year they felt they had “experienced discrimination, been prevented from doing something, or been hassled or made to feel inferior” because of their race or ethnicity.
In comparison with those who did not experience discrimination, those who experienced discrimination had a 1.5-fold greater risk of mild AUD, a 1.6-fold greater risk of moderate AUD, and a 2.3-fold greater risk of severe AUD.
“Strategies to reduce risk for severe AUD should include efforts to minimize the occurrence and impact of interpersonal and institutional racism,” they concluded.
Glass JE, Williams EC, and Oh H. Racial/Ethnic Discrimination and Alcohol Use Disorder Severity Among United States Adults. Drug Alcohol Depend. August 10, 2020. [Online ahead of print]
COVID-19 Education, Proactive Coping Can Reduce Pandemic-Related Stress
iStock/FG Trade
A study in the Journal of Gerontology: Psychological Science found that adults who have more knowledge about COVID-19 may have less pandemic-related stress on average. The study also reported that older adults could help reduce pandemic stress by making proactive stress coping plans.
Investigators at North Carolina State University and the Georgia Institute of Technology surveyed 515 adults aged 20 to 79 from across the United States using Amazon’s Mechanical Turk online marketplace. The survey assessed the participants’ knowledge about the COVID-19 virus, their stress and anxiety about the pandemic, and any protective measures they were taking.
The survey results showed that regardless of age, participants who knew more about the virus had lower levels of COVID-related stress. Interestingly, overall stress levels did not differ by age groups, despite older adults being more likely to have adverse outcomes with infection.
The investigators found that adults over 50 had higher levels of COVID-related anxiety compared with younger adults, but also received more stress-reducing benefits from proactive coping strategies, such as setting goals or making plans for potential health events. Older adults also scored slightly higher on the knowledge quiz.
“Given the potential continuing and long-term impact of this pandemic, working toward support programs for older adults in terms of coping skills may be fruitful,” the investigators wrote.
Pearman A, Hughes ML, Smith EL, Neupert SD. Age Differences in Risk and Resilience Factors in COVID-19-Related Stress. J Gerontol B Psychol Sci Soc Sci. August 3, 2020. [Online ahead of print]
Bumetanide May Improve Repetitive Behaviors, But Not Other ASD Symptoms
iStock/Geber86
Some preliminary clinical studies have suggested the diuretic bumetanide can help reduce symptoms of autism spectrum disorder (ASD). These early studies used a general autism screening questionnaire as the outcome; they did not specifically assess core ASD symptoms, such as an atypical response to sensory inputs.
A randomized clinical study involving 92 children aged 7 to 15 with ASD now shows bumetanide is not superior to placebo in broad symptom improvement, but it may help some children with strong repetitive behaviors. The results were published in the Journal of the American Academy of Child and Adolescent Psychiatry.
Investigators at University Medical Centre Utrecht in the Netherlands and colleagues randomized participants to receive either twice-daily bumetanide or placebo for 91 days.
At the study’s end, they assessed for changes in the children’s social interactions, sensory responses, repetitive behaviors, and irritability. Bumetanide was not better than placebo for any of these core symptoms except for repetitive behaviors. Follow-up analysis suggested that girls taking bumetanide showed greater improvements in repetitive behaviors than boys taking the medication.
These results highlight how the heterogeneity of ASD can influence clinical trial research and the need to obtain functional data, such as brain scans, to understand how the treatments work, the authors wrote. “For now, we conclude that random off-label prescription of bumetanide for children with ASD is not recommended by our findings,” they concluded.
Sprengers JJ, van Andel DM, Zuithoff NP, et al. Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase Two, Superiority Trial. J Am Acad Child Adolesc Psychiatry. July 27, 2020. [Online ahead of print]
OUD Patients With Infections Often Stay at Hospital Longer
iStock/shapecharge
People with opioid use disorder (OUD) hospitalized for serious bacterial infections spend more time in the hospital and are more likely to be discharged to another facility rather than home, according to a study in PLoS Medicine. These discharge disparities occurred despite OUD patients being younger, having fewer comorbidities, and requiring less surgery on average than other patients with infections.
“These disparities in hospital stays and destinations after discharge suggest that people with opioid use disorder may lack post-discharge options such as skilled nursing facilities or home care for antibiotic infusions,” wrote the study authors. “Consideration should be given to expanding discharge options for people with opioid use disorder to reduce costly hospital stays and provide equitable care for serious infections.”
Investigators at Brigham and Women’s Hospital and colleagues used data from the 2016 National Inpatient Sample (which contains health information on approximately 8 million hospitalizations each year) to analyze discharge trends for serious bacterial infections such as internal abscesses. They identified 95,470 infection-related hospitalizations in their sample, of which 8% involved patients with OUD.
The average length of stay was 12.5 days for OUD patients compared with 8.1 days for patients without OUD. Due to this extra time, the average cost of treating infection in a patient with OUD was almost $24,000 more per stay, despite lower daily costs.
Patients with OUD were also less likely to be discharged home compared with patients without OUD (45.3% vs. 63.1%) and discharged with home health services (10.8% vs. 27.8%). They were more likely to have a patient-directed discharge against medical advice (19.1% vs. 2.6%) or to be transferred to another acute care hospital (6.8% vs. 4.5%). ■
Kim JH, Fine DR, Li L, et al. Disparities in United States Hospitalizations for Serious Infections in Patients With and Without Opioid Use Disorder: A Nationwide Observational Study. PLoS Med. 2020; 17(8): e1003247.
Information & Authors
Information
Published In
Psychiatric News
History
Published online: 29 September 2020
Published in print: September 19, 2020 - October 2, 2020
Keywords
- autism spectrum disorder
- Alzheimer’s
- amyloid
- biomarker
- PET scan
- depression
- anxiety
- suicidality
- COVID-19
- stress
- anxiety
- education
- proactive coping
- setting goals
- bumetanide
- autism spectrum disorder
- ASD
- irritability
- sensory response
- repetitive behaviors
- clinical trial
- opioid use disorder
- OUD
- bacterial infection
- sepsis
- hospital discharge
- post-acute care
- health disparities
- epigenetic
- post-traumatic stress disorder
- trauma survivor
- NTRK2 gene
- memory retrieval
- intrusive thoughts
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
There are no citations for this item
View Options
View options
Get Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).